Literature DB >> 74608

Identification of dihydrofolate reductase in human central-nervous-system tumours.

H T Abelson, M Fosburg, C Gorka, P Kornblith.   

Abstract

Ten primary and two metastatic central-nervous system (C.N.S.) tumours were assayed. They all contained dihydrofolate reductase. This finding provides a biochemical rationale for antifolate therapy of C.N.S. tumours by methotrexate.

Entities:  

Mesh：

Substances：

Year:  1978        PMID： 74608     DOI： 10.1016/s0140-6736(78)90615-3

Source DB:  PubMed          Journal:  Lancet        ISSN： 0140-6736            Impact factor:   79.321


  2 in total

1.  The inability of oral leucovorin to elevate CSF 5-methyl-tetrahydrofolate following high dose intravenous methotrexate therapy.

Authors:  J Allen; G Rosen; H Juergens; B Mehta
Journal:  J Neurooncol       Date:  1983       Impact factor: 4.130

2.  Phase I clinical trial and pharmacology of 2,4-diamino-5-(3',4'-dichlorophenyl)-6-methylpyrimidine (metoprine) (DDMP) and folinic acid (CF).

Authors:  R de Jager; D Dupont; J J Rodzynek; C Dorlet; G Lagrange
Journal:  Cancer Chemother Pharmacol       Date:  1981       Impact factor: 3.333
  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.